Posts Tagged ‘biosimilar’

This is a guest post from Keith Bradbury, Executive Director of Drug Information at Medco Health Solutions, Inc. Biosimilar drugs to gain greater priority as decade progresses The Patient Protection and Affordable Care Act will heighten the degree of competition in the field of biotech drugs, a fast growing area of drug therapy that is […]

Share this:

Like this:

Biotechnology Industry Organization CEO Jim Greenwood appeared on CNBC’s SquawkBox defending the case for data exclusivity protection for novel biologic drugs. The video appears below. Interestingly, he used the Aspirin vs. Epogen comparison from my book, Building Biotechnology, when he was explaining the difference between small molecule and biologic drugs to members of congress.